arrow
B

Bastian Czogalla

university of munich
H指数:19
被引数:1,109

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ablation compared with excision in the surgical management of peritoneal endometriosis: a retrospective study of pain, re-operation, and pregnancy outcomes

与切除术相比,在腹膜子宫内膜异位症的外科管理中消融术的比较:一项关于疼痛、再手术和妊娠结局的回顾性研究

2026-02-021
OAAI
Organoid platinum-resistance model identifies KRT17 as a biomarker of targeted therapy in ovarian cancer

类器官铂耐药模型鉴定KRT17为卵巢癌靶向治疗的生物标志物

2025-11-100
OAAI
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy

靶向CD47检查点阻断,使用一种针对mesothelin的抗体构建体,以增强针对实体瘤的特异性免疫疗法

2025-05-220
OA
Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects

PARP抑制剂引起的昼夜节律紊乱与卵巢癌患者的治疗毒性相关,并且是副作用发生的预测因子

2025-05-160
OA
Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group

治疗伴有转移性或复发性宫颈癌的患者:AGO研究组质量保证项目的结果

2024-09-010
PRE
Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies

低级别浆液性卵巢癌一线治疗中的抗血管生成疗法:AGO-OVAR 11/12/16前瞻性研究的探索性荟萃分析

2024-09-010
PRE
Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cells

子宫内膜癌中调节性T细胞的存在预示着较差的总生存期并促进肿瘤细胞的进展

2022-09-137
OAAI
The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine

血小板活化因子受体与卵巢癌患者预后的关系及其卢帕他定的实验抑制作用

CELLS
IF5.2
2021-09-078
OAAI
Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs)

与乳腺肿瘤基质巨噬细胞 (BTSMs) 相比,乳腺脂肪组织巨噬细胞 (BATMs) 与乳腺癌生存率的相关性更强。

2021-04-138
OAAI
Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group

复发性卵巢癌患者的原发性铂类耐药及其对预后的影响: 来自NOGGO研究组的三项前瞻性试验的分析

2021-01-018
OAAI